Loading...

OSE Immunotherapeutics

DB:6OP
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6OP
DB
€60M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

OSE Immunotherapeutics SA, a biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
6OP Share Price and Events
7 Day Returns
-1.2%
DB:6OP
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-5.2%
DB:6OP
-9.2%
DE Biotechs
-6.7%
DE Market
6OP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
OSE Immunotherapeutics (6OP) -1.2% -2.2% 10.8% -5.2% -41.9% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 6OP outperformed the Biotechs industry which returned -9.2% over the past year.
  • 6OP outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
6OP
Industry
5yr Volatility vs Market

Value

 Is OSE Immunotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of OSE Immunotherapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for OSE Immunotherapeutics.

DB:6OP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:6OP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6.7%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 33%) (7.46%))
1.354
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.35
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.354 * 6.65%)
9.23%

Discounted Cash Flow Calculation for DB:6OP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for OSE Immunotherapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:6OP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.23%)
2019 -43.50 Analyst x1 -39.82
2020 6.40 Analyst x1 5.36
2021 6.41 Est @ 0.11% 4.92
2022 6.42 Est @ 0.14% 4.51
2023 6.43 Est @ 0.17% 4.13
2024 6.44 Est @ 0.19% 3.79
2025 6.45 Est @ 0.2% 3.48
2026 6.47 Est @ 0.21% 3.19
2027 6.48 Est @ 0.21% 2.93
2028 6.49 Est @ 0.22% 2.68
Present value of next 10 years cash flows €-4.84
DB:6OP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €6.49 × (1 + 0.23%) ÷ (9.23% – 0.23%)
€72.27
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €72.27 ÷ (1 + 9.23%)10
€29.88
DB:6OP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €-4.84 + €29.88
€25.04
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €25.04 / 14.77
€1.7
DB:6OP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:6OP represents 0.98765x of ENXTPA:OSE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.98765x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 1.70 x 0.98765
€1.67
Value per share (EUR) From above. €1.67
Current discount Discount to share price of €4.00
= -1 x (€4.00 - €1.67) / €1.67
-138.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of OSE Immunotherapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for OSE Immunotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are OSE Immunotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:6OP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.38
ENXTPA:OSE Share Price ** ENXTPA (2019-04-18) in EUR €4.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of OSE Immunotherapeutics.

DB:6OP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:OSE Share Price ÷ EPS (both in EUR)

= 4.05 ÷ 0.38

10.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OSE Immunotherapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • OSE Immunotherapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does OSE Immunotherapeutics's expected growth come at a high price?
Raw Data
DB:6OP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 10.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-15.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

DB:6OP PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 10.8x ÷ -15.6%

-0.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OSE Immunotherapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on OSE Immunotherapeutics's assets?
Raw Data
DB:6OP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.18
ENXTPA:OSE Share Price * ENXTPA (2019-04-18) in EUR €4.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:6OP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:OSE Share Price ÷ Book Value per Share (both in EUR)

= 4.05 ÷ 4.18

0.97x

* Primary Listing of OSE Immunotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • OSE Immunotherapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess OSE Immunotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. OSE Immunotherapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is OSE Immunotherapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-15.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is OSE Immunotherapeutics expected to grow at an attractive rate?
  • OSE Immunotherapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • OSE Immunotherapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • OSE Immunotherapeutics's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:6OP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:6OP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -15.6%
DB:6OP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 1.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:6OP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:6OP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 42 6 1
2022-12-31 20 -9 1
2021-12-31 0 -20 1
2020-12-31 0 -19 2
2019-12-31 25 6 2
DB:6OP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 24 1 5
2018-09-30 24 0 5
2018-06-30 24 -2 5
2018-03-31 16 -5 -3
2017-12-31 7 -8 -11
2017-09-30 5 -2 -10
2017-06-30 3 4 -10
2017-03-31 2 2 5
2016-12-31 0 1 21
2016-09-30 0 -2 21
2016-06-30 0 -5 22
2016-03-31 0 -5 8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • OSE Immunotherapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • OSE Immunotherapeutics's revenue is expected to grow by 1.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:6OP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from OSE Immunotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6OP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.26 0.26 0.26 1.00
2022-12-31 -0.44 -0.44 -0.44 1.00
2021-12-31 -0.94 -0.94 -0.94 1.00
2020-12-31 -1.12 -0.90 -1.33 2.00
2019-12-31 0.42 0.50 0.34 2.00
DB:6OP Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 0.38
2018-09-30 0.35
2018-06-30 0.33
2018-03-31 -0.20
2017-12-31 -0.73
2017-09-30 -0.72
2017-06-30 -0.71
2017-03-31 0.39
2016-12-31 1.65
2016-09-30 1.86
2016-06-30 2.11
2016-03-31 0.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if OSE Immunotherapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess OSE Immunotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
OSE Immunotherapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has OSE Immunotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare OSE Immunotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • OSE Immunotherapeutics's year on year earnings growth rate has been positive over the past 5 years.
  • OSE Immunotherapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • OSE Immunotherapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
OSE Immunotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from OSE Immunotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:6OP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 24.46 5.49 4.43 15.06
2018-09-30 24.45 5.10 4.49 14.83
2018-06-30 24.44 4.71 4.56 14.60
2018-03-31 15.56 -2.89 4.61 14.61
2017-12-31 6.68 -10.50 4.65 14.62
2017-09-30 4.94 -10.34 4.56 12.84
2017-06-30 3.19 -10.18 4.47 11.05
2017-03-31 1.79 5.24 3.96 8.09
2016-12-31 0.38 20.67 3.45 5.13
2016-09-30 0.21 21.27 2.99 4.24
2016-06-30 0.04 21.86 2.52 3.34
2016-03-31 0.02 8.14 2.85 2.79
2015-12-31 0.00 -5.58 3.18 2.24
2015-09-30 0.00 -5.35 2.82 2.37
2015-06-30 0.00 -5.12 2.47 2.49
2015-03-31 0.00 -3.98 1.63 2.25
2014-12-31 -2.84 0.80 2.01
2014-09-30 -1.81 0.56 1.24
2014-06-30 -0.78 0.32 0.46
2014-03-31 -0.52 0.21 0.31
2013-12-31 -0.25 0.10 0.15
2012-12-31 -1.72 0.16 1.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • OSE Immunotherapeutics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • OSE Immunotherapeutics used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • OSE Immunotherapeutics has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess OSE Immunotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
OSE Immunotherapeutics has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is OSE Immunotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up OSE Immunotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • OSE Immunotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • OSE Immunotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of OSE Immunotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from OSE Immunotherapeutics Company Filings, last reported 3 months ago.

DB:6OP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 61.75 4.46 12.43
2018-09-30 61.75 4.46 12.43
2018-06-30 64.77 4.75 18.65
2018-03-31 64.77 4.75 18.65
2017-12-31 55.45 4.89 12.53
2017-09-30 55.45 4.89 12.53
2017-06-30 58.65 3.88 20.52
2017-03-31 58.65 3.88 20.52
2016-12-31 64.53 1.78 17.77
2016-09-30 64.53 1.78 17.77
2016-06-30 67.94 2.19 15.28
2016-03-31 67.94 2.19 15.28
2015-12-31 14.48 0.98 15.13
2015-09-30 14.48 0.98 15.13
2015-06-30 16.68 1.35 18.36
2015-03-31 16.68 1.35 18.36
2014-12-31 -0.80 1.18 1.11
2014-09-30 -0.80 1.18 1.11
2014-06-30 1.47 1.16 2.74
2014-03-31 1.47 1.16 2.74
2013-12-31 -0.86 1.15 0.28
2012-12-31 -0.63 0.83 0.19
  • OSE Immunotherapeutics's level of debt (7.2%) compared to net worth is satisfactory (less than 40%).
  • OSE Immunotherapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Debt is well covered by operating cash flow (24.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 34.4x coverage).
X
Financial health checks
We assess OSE Immunotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. OSE Immunotherapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is OSE Immunotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from OSE Immunotherapeutics dividends.
If you bought €2,000 of OSE Immunotherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate OSE Immunotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate OSE Immunotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:6OP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:6OP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as OSE Immunotherapeutics has not reported any payouts.
  • Unable to verify if OSE Immunotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of OSE Immunotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as OSE Immunotherapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess OSE Immunotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can OSE Immunotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. OSE Immunotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of OSE Immunotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alexis Peyroles
COMPENSATION €973,582
TENURE AS CEO 1 years
CEO Bio

Mr. Alexis Peyroles has served as Chief Executive Officer of OSE Immunotherapeutics SA since April 12, 2018 and serves as its Director. He served as Chief Operating Officer for Finance, Business Development & Operations at OSE Pharma SA from May 31, 2016 to April 12, 2018. Mr. Peyroles served as Chief Financial Officer of OSE Pharma SA from 2013 to May 31, 2016. He served as Vice President of Financial Control and Member of Management Board at Guerbet S.A. He has more than 15 years of international experience in Pharmaceuticals working for Sanofi in Japan and Eastern Europe then Guerbet in France and Brazil. Mr. Peyroles worked for two Biotechs in France. He graduated from EDHEC business school and with an MBA from Imperial College London.

CEO Compensation
  • Alexis's compensation has increased in line with OSE Immunotherapeutics recently becoming profitable.
  • Alexis's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the OSE Immunotherapeutics management team in years:

1
Average Tenure
  • The average tenure for the OSE Immunotherapeutics management team is less than 2 years, this suggests a new team.
Management Team

Dominique Costantini

TITLE
Founder
COMPENSATION
€285K
TENURE
7.3 yrs

Alexis Peyroles

TITLE
Director & CEO
COMPENSATION
€974K
TENURE
1 yrs

Maryvonne Hiance

TITLE
Vice Chairman of the Board & Director of Strategy
COMPENSATION
€14K
AGE
69
TENURE
1 yrs

Jean Theron

TITLE
Consultant

Anne-Laure Autret-Cornet

TITLE
Chief Financial Officer

Nicolas Poirier

TITLE
Chief Scientific Officer
TENURE
1 yrs

Alain Chatelin

TITLE
Medical Director and Member of the Scientific Board

Bérangère Vasseur

TITLE
Chief Medical Officer Immuno-Oncology
TENURE
1.3 yrs

Julien Perrier

TITLE
Chief Commercial Officer
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the OSE Immunotherapeutics board of directors in years:

5
Average Tenure
  • The tenure for the OSE Immunotherapeutics board of directors is about average.
Board of Directors

Alexis Peyroles

TITLE
Director & CEO
COMPENSATION
€974K

Maryvonne Hiance

TITLE
Vice Chairman of the Board & Director of Strategy
COMPENSATION
€14K
AGE
69
TENURE
2.9 yrs

Alain Chatelin

TITLE
Medical Director and Member of the Scientific Board

Jean-Patrick Demonsang

TITLE
Director
COMPENSATION
€29K
AGE
64
TENURE
5 yrs

Dominique Costantini

TITLE
Founder
COMPENSATION
€285K
TENURE
1 yrs

Wolf-Hervé Fridman

TITLE
Chairman of the Scientific Board
TENURE
5.4 yrs

Walter Flamenbaum

TITLE
Director
COMPENSATION
€14K

John Nemunaitis

TITLE
Member of the Scientific Board

Alex Sette

TITLE
Member of the Scientific Board

Gérard Tobelem

TITLE
Director
COMPENSATION
€29K
TENURE
5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess OSE Immunotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. OSE Immunotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

OSE Immunotherapeutics SA, a biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. It offers Memopi technology to activate the immune system based on a patented combination of neo-epitopes; Tedopi, a T specific immunotherapy that is in Phase III clinical stage for the treatment of lung cancer in the United States, Israel, and Europe, as well as in Phase II clinical trials to treat ovarian, colon, or breast cancers. OSE Immunotherapeutics SA has a strategic research collaboration with Memorial Sloan Kettering Cancer Center to explore IL-7R directed immunotherapy OSE-703 for solid tumors in non-small cell lung cancer; a license and collaboration agreement with Boehringer Ingelheim to develop OSE-172, a checkpoint inhibitor antibody targeting myeloid lineage cells; and a research collaboration agreement with Léon Bérard Cancer Center to use artificial intelligence (AI)-based bioanalysis and bioinformatics to identify targets in immuno-oncology. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

Details
Name: OSE Immunotherapeutics SA
6OP
Exchange: DB
Founded:
€59,807,196
14,767,209
Website: http://www.ose-immuno.com
Address: OSE Immunotherapeutics SA
22, boulevard Benoni Goullin,
Nantes,
Pays de la Loire, 44200,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA OSE Common Stock Euronext Paris FR EUR 30. Mar 2015
OTCPK ORPO.F Common Stock Pink Sheets LLC US USD 30. Mar 2015
DB 6OP Common Stock Deutsche Boerse AG DE EUR 30. Mar 2015
LSE 0RAD Common Stock London Stock Exchange GB EUR 30. Mar 2015
Number of employees
Current staff
Staff numbers
28
OSE Immunotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:17
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.